Phase II Study of Metronomic Chemotherapy with Thalidomide, Carboplatin-Vincristine-Fluvastatin in the Treatment of Brain Stem Tumors in Children

Archives of Medical Research

Volumn 39, Issue 7, 2008, Pages 655-662

  López Aguilar, Enrique ^a   Sepúlveda Vildósola, Ana Carolina ^a   Betanzos Cabrera, Yadira ^a   Rocha Moreno, Yael Guadalupe ^a   Gascón Lastiri, Graciela ^a   Rivera Márquez, Hugo ^a   Wanzke del Angel, Volkmar ^a   Cerecedo Díaz, Fernando ^a   Cruz Yañez, Hermilo de la ^a  

^a HOSPITAL DE PEDIATRÍA   (Mexico)

Author keywords

Brain stem tumors; Carboplatin; Fluvastatin; Metronomic chemotherapy; Thalidomide; Vincristine

Indexed keywords

CARBOPLATIN; FLUINDOSTATIN; THALIDOMIDE; VINCRISTINE;

ADOLESCENT; ARTICLE; ASTROCYTOMA; BRAIN STEM TUMOR; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CHILD; CLINICAL ARTICLE; DRUG HYPERSENSITIVITY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; GLIOBLASTOMA; HUMAN; KARNOFSKY PERFORMANCE STATUS; MALE; METRONOMIC CHEMOTHERAPY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; QUALITY OF LIFE; THROMBOCYTOPENIA; TOXICITY; TREATMENT RESPONSE; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN STEM NEOPLASMS; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMANS; INDOLES; INFANT; MAGNETIC RESONANCE IMAGING; MALE; QUALITY OF LIFE; SURVIVAL RATE; THALIDOMIDE; VINCRISTINE;

EID: 49949097870     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2008.05.008     Document Type: Article

References (35)

1. Sepulveda-Vildosola A.C., Rivera-Luna R., Medina A., Aguilar M., and Lopez-Aguilar E. Epidemiology of central nervous system tumors in children. Report of the Mexican Brain Tumor Study Group. Pediatr Blood and Cancer 47 (2006) 454 (PE 003)
2. Strother D.R., Poplack I.F., Fisher P.G., et al. Tumors of the central nervous system. In: Pizzo P., and Poplack D. (Eds). Principles and Practice of Pediatric Oncology. 4th (2002), Lippincott Williams & Wilkins, Philadelphia 715-815
3. Fajardo G.A. Cáncer en el niño. Epidemiología descriptiva. 1st ed. (2002), Cuellar, México p. 421
4. Pollack I.F. Brain tumors in children. N Engl J Med 22 (1994) 1500-1507
5. Lynn A., and Gloeckler R. Childhood Cancer Mortality. National Cancer Institute. SEER Pediatric Monograph Review 6 (1973-1996) 165-170
6. Strother D.R., Poplack I.F., and Fisher P.G. Tumors of the central nervous system. In: Pizzo P.A., and Poplack D.G. (Eds). Principles and Practice of Pediatric Oncology. 4th ed. (2002), Lippincott, Williams and Wilkins, Philadelphia 751-824
7. Mandell L., Kadota R., Freeman C., Douglass E.C., Fontanesi J., Cohen M.E., et al. There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of Pediatric Oncology Group Phase III trial comparing conventional vs. hyperfractionated radiotherapy. Int J Radiat Oncol Phys 43 (1999) 959-964
8. Allen J., Siffert J., Nirenber A., and Jakacki R. A phase I/II study of carboplatin combined with hyperfractionated radiotherapy for brainstem gliomas. Cancer 86 (1999) 1064-1069
9. Freeman C.R., Kepner J., Kun L.E., Sanford R.A., Kadota R., Mandell L., et al. A detrimental effect of a combined chemotherapy-radiotherapy approach in children with diffuse intrinsic brain stem gliomas?. Int J Radiat Oncol Biol Phys 47 (2000) 561-564
10. Marcus K.J., Dutton S.C., Barnes P., Coleman C.N., Pomeroy S.L., Goumnerova L., et al. A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brain stem gliomas. In J Radiat Oncol Biol Phys 55 (2003) 1182-1185
11. Benesch M., Lackner H., Moser A., Kerbl R., Schwinger W., Oberbauer R., et al. Outcome and long-term side effects after synchronous radio-chemotherapy for childhood brain stem gliomas. Pediatr Neurosurg 35 (2001) 173-180
12. Bronicser A., and Gajjar A. Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist. Oncologist 9 (2004) 197-206
13. Bronicser A., Iacono L., Chintagumpala M., Fouladi M., Wallace D., Bowers D.C., et al. Role of temozolamide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98). Cancer 103 (2005) 133-139
14. de Aquino-Gorayeb M.M., Aisen S., Nadalin W., Panico Gorayeb R., and de Andrade Carvalho H. Treatment of childhood diffuse brain stem tumors: comparison of results in different treatment modalities. Clin Transl Oncol 8 (2006) 45-49
15. Fouladi M., Nicholson H.S., Zhou T., Laningham F., Helton K.J., Holmes E., et al. Children's Oncology Group. Cancer 110 (2007) 2535-2541
16. López-Aguilar E., Sepulveda-Vildosola A.C., Rivera-Marquez H., Cerecedo-Díaz F., Valdez-Sanchez M., Delgado-Huerta S., et al. Preirradiation ifosfamide, carboplatin and etoposide for the treatment of high grade astrocytomas in children. Child Nerv Syst 19 (2003) 818-823
17. Bergers G., Javaherian K., Lo K.M., Flokman J., and Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284 (1999) 808-812
18. Hanahan D., Bergers G., and Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105 (2000) 1045-1047
19. Flokins C., Man S., Xu P., Shaked Y., Hicklin D., and Kerbel R.S. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in gliomas xenograft tumors. Cancer Res 67 (2007) 3560-3564
20. Sterba J., Pavelka Z., and Stampa P. Concomitant radiotherapy and metronomic temozolamide in pediatric high-risk brain tumors. Neoplasm 49 (2002) 117-120
21. Herrlinger U., Rieger J., Steinbach J.P., Nägele T., Dichgans J., and Weller M. UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma. J Neurooncol 71 (2005) 295-299
22. Kong D.S., Lee J.I., Kim W.S., Son M.J., Lim do H., Kim S.T., et al. A pilot study of metronomic temozolamide treatment in patients with recurrent temozolamide-refractory glioblastoma. Oncol Rep 16 (2006) 1117-1121
23. Kesari S., Schiff D., Doherty L., Gigas D.C., Batchelor T.T., Muzikansky A., et al. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro Oncol 9 (2007) 354-963
24. UICC. Evaluation of Response to Treatment. Clinical Oncology (1987) 112
25. Miller A.B., Hoogstrantom B., and Staquet M. Reporting results of cancer treatment. Cancer 47 (1981) 207
26. Kadota R. Perspectives on investigational chemotherapy and biologic therapy for childhood brain tumors. J Pediatr Hematol Oncol 18 (1996) 13-22
27. Lopez-Aguilar E., Sepulveda-Vildósola A.C., Rivera-Marquez H., Cerecedo-Diaz F., Valdez-Sanchez M., and Villasis-Keever M.A. Security and maximal tolerated doses of fluvastatin in pediatric cancer patients. Arch Med Res 30 (1999) 128-131
28. Lopez-Aguilar E., Rivera-Marquez H., and Sepulveda-Vildosola A.C. Fluvastatin as a rescue treatment for low-grade astrocytomas in children. Report of three cases. Proc Am Soc Clin Oncol (2000) 19 (abstr. 672)
29. Kohka-Takashi H., Weitz-Scmidt G., Iwagaki H., Yoxhino T., Tanaka N., and Nishibori M. Hypothesis: the antitumor activities of statins may be mediated by IL-18. J Leukocyte Biol 80 (2006) 215-216
30. Paumelle R., Blanquart C., Briand O., Barbier O., Duhem C., Woerly G., et al. Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-α via inhibition of the protein kinase C signaling pathway. Circ Res 98 (2006) 361-369
31. Hannahan D. Patterns and emerging mechanisms on the angiogenesis switch during tumorigenesis. Cell 86 (1996) 353-364
32. Jouanneau E. Angiogenesis and gliomas: current issues and development of surrogate markers. Neurosurgery 62 (2008) 31-52
33. Teo S., Colburn W., Tracewell W., Kook K., Stirling D., Jaworsky M., et al. Clinical pharmacokinetics of thalidomide. Clin Pharmacokin 43 (2004) 311-327
34. D'Amato R.J., Loughnan M.S., Flynn E., and Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91 (1994) 4082-4085
35. Yu D., Dahl G., Shames R., and Fisher P. Weekly dosing of carboplatin increases risk of allergy in children. J Pediatr Hematol Oncol 23 (2001) 349-352